Semax is authorised as a medicine in Russia for cerebrovascular and cognitive indications, with a Russian clinical literature spanning several decades. Independent Western clinical trials and broader regulatory authorisation are limited. It remains a major research compound of interest in neuroprotection and cognitive enhancement studies.
Published studies — concentrated in Russian-language literature — have explored:
Stroke and cerebrovascular research: Clinical studies in ischemic stroke recovery cohorts, with reported effects on neurological recovery.
Cognitive enhancement: Studies on attention, memory, and cognitive performance in clinical and healthy cohorts.
Neuroprotection: Preclinical models of neuronal injury and oxidative stress.
BDNF and neurotrophin research: Effects on neurotrophic factor expression in animal models.
ADHD research: Small clinical studies in attention-related conditions in paediatric cohorts.